ALDR - Alder Biopharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.41
+1.05 (+8.50%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.36
Open12.38
Bid12.50 x 800
Ask13.40 x 800
Day's Range12.26 - 13.51
52 Week Range9.44 - 20.87
Volume1,777,283
Avg. Volume913,038
Market Cap916.26M
Beta (3Y Monthly)3.42
PE Ratio (TTM)N/A
EPS (TTM)-4.48
Earnings DateJul 27, 2017 - Jul 28, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.93
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Alder BioPharmaceuticals® Appoints Paul Streck, M.D. Chief Medical Officer

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Paul Streck, M.D., as chief medical officer (CMO), effective January 21, 2019.  He will report to Bob Azelby, Alder’s president and chief executive officer. Dr. Streck brings more than 25 years of experience in drug development, regulatory and medical affairs leadership across both large and small publicly traded biopharmaceutical companies.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    # Alder Biopharmaceuticals Inc ### NASDAQ NMS:ALDR View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ALDR totaled $135 million. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Will Biogen Jump On This Biotech Stock Amid Buying Spree?
    Investor's Business Daily5 days ago

    Will Biogen Jump On This Biotech Stock Amid Buying Spree?

    Alder Biopharmaceuticals could eventually capture 15%-20% of the market for migraine prevention, an analyst said Monday, suggesting the biotech stock might be a good fit for giant Biogen.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    # Alder Biopharmaceuticals Inc ### NASDAQ NMS:ALDR View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding ALDR are favorable, with net inflows of $3.54 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire19 days ago

    Alder BioPharmaceuticals® to Present at the 37th Annual J.P. Morgan Healthcare Conference

    BOTHELL, Wash., Dec. 31, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • Markitlast month

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    # Alder Biopharmaceuticals Inc ### NASDAQ NMS:ALDR View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on November 27. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding ALDR are favorable, with net inflows of $1.32 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Alder Biopharmaceuticals Inc (ALDR) A Good Stock To Buy?
    Insider Monkeylast month

    Is Alder Biopharmaceuticals Inc (ALDR) A Good Stock To Buy?

    At Insider Monkey, we pore over the filings of more than 700 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In […]

  • GlobeNewswirelast month

    Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOTHELL, Wash., Dec. 14, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • Markitlast month

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    # Alder Biopharmaceuticals Inc ### NASDAQ NMS:ALDR Score: Negative (20) 42 days at current score. Downgraded from Neutral on November 2nd 2018 View full report here! ## Summary * This company ranked negatively compared to the Healthcare sector despite 1 positive IHS Markit Category * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on November 27. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold ALDR had net inflows of $566 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzingalast month

    The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...

  • GlobeNewswirelast month

    Alder BioPharmaceuticals® Appoints Carlos Campoy Chief Financial Officer

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Carlos Campoy as Chief Financial Officer, effective December 12, 2018. “Carlos is a highly experienced, performance-driven CFO with deep financial and operational expertise across competitive markets,” said Bob Azelby, President and Chief Executive Officer.

  • See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDR

  • See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDR

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALDR earnings conference call or presentation 5-Nov-18 10:00pm GMT

    Q3 2018 Alder Biopharmaceuticals Inc Earnings Call

  • See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDR

  • GlobeNewswire2 months ago

    Alder BioPharmaceuticals® to Present at Two Upcoming November Investor Conferences

    BOTHELL, Wash., Nov. 08, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • Associated Press2 months ago

    Alder BioPharmaceuticals: 3Q Earnings Snapshot

    On a per-share basis, the Bothell, Washington-based company said it had a loss of 91 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results

    - Biologics License Application (BLA) submission on track for Q1 2019 - - Robust manufacturing package for BLA submission to include positive results from pharmacokinetic.

  • GlobeNewswire3 months ago

    Alder BioPharmaceuticals® to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

    BOTHELL, Wash., Oct. 29, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDR

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Alder BioPharmaceuticals® Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab

    Alder Biopharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced positive results from a comparative pharmacokinetic (PK) study intended to support the comparability evaluation of the clinical supply for eptinezumab and its planned commercial supply. Eptinezumab is Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). “We are pleased that the PK study has met our objective of demonstrating the comparability of eptinezumab,” said Dr. Eric Carter, interim chief medical officer of Alder.

  • The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
    Zacks3 months ago

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

  • 4 Healthcare Stocks Thriving on Venture Capital Funding
    Zacks3 months ago

    4 Healthcare Stocks Thriving on Venture Capital Funding

    A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.

  • See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDR